HIPERHOMOSISTEINEMIA SEBAGAI RISIKO PENYAKIT JANTUNG KORONER
DOI:
https://doi.org/10.21776/ub.jkb.2005.021.03.1Abstract
The elevation of total plasma homocysteine is associated with increase of risk for cardiovascular disease, cerebrovascular disease, and atherothrombosis in peripheral arteries. Several prospective and retrospective studies had conformed the positive association between hyperhomocysteinemia and risk for cardiovascular disease. However, it whether hyperhomocysteinemia is an independent riskfactor for cardiovascular disease associated with  the others risk factors still become a question. The aim of this study was to identify the association between hyperhomocysteinemia and increased risk for cardiovascular disease. A matched case-control study based on 50 consecutive adult  patients aged more than 18 years old who admitted in Dr. SardjitoGeneral Hospital by first acute coronary syndrome.Fifty comparison control subjects were randomly selected age and gender group-matched patients admitted caused by conditions other than cardiovascular disease to the same hospital. Each case was enrolled, and comparison subject was randomly selected. Fasting blood samples for homocysteine were obtained from both groups. Chi square test, McNemar chi square test, and independent t test had been used in univariate analysis. Confounding factors had been analysed usingDownloads
References
DAFTAR KEPUSTAKAAN
Irawan B. Patofisiologi Sindrom Koroner Akut dalam Kumpulan Makalah Mini Course Kegawatan Kardiologi.
Yogyakarta: Bagian Penyakit Dalam FK UGM-RS DR. Sardjito;2002; 1-4.
Ismail D. Patofisiologi Sindrom Koroner Akut. Dalam Bawazier LA, Alwi I, Syam AF (eds): Prosiding Simposium
Pendekatan Holistik Penyakit Kardiovaskular. Jakarta: Pusat Informasi dan Penerbitan Bagian Ilmu Penyakit Dalam FK-UI; 2001;22-31
Makmun LH. Faktor Risiko Penyakit Jantung Koroner. The First Symposium Cardiovascular Respiratory Immunology
from Pathogenesis to Clinical Application; 2002; 111-116.
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: An Independent
Risk Factor for Vascular Disease. N. Eng J Med. 1991; 324: 1149-1155.
Boushey CJ, Bereford SA, Omenn GS, Motulsky AG. A Quantitative Assesment of Plasma Homocysteine as a Risk
Factor for Vascular Disease. JAMA. 1995; 274: 1049-1056.
Graham IM, Daly LE, Refsum HM. Plasma Homocysteine as a Risk Factor for Vascular Disease. JAMA. 1997;227:1775-1781.
Christen WG, Ajani UA, Glyn RJ, Hennekens CH. Blood Levels of Homocysteine and Increased Risks ofCardiovascular
Disease. Causal or Causal ?. Arch Intern Med. 2000;160:422.
Wald NJ, Watt HC, Law MR, Hennessy E, McPartlin J, Scott JM. Homocysteine And Ischaemic Heart Disease: Result of
A Prospective Study with Implications Regarding Prevention. Arch Intern Med. 1998; 158: 862-867.
Rosenson RS, & Kang DS. Hyperhomocysteinemia, Atherosclerosis, and Venous Thromboembolism. In Up to Date Vol. 10 No. 1 “www.Up to Date. Com†(800) 998-6374; 2002;(781):237-4788.
Schlesselman JJ. Case-Control Studies, Design, Conduct, Analysis. New York: Oxford University Press; 1982
Mansoor MA, Svardal AM, Schneede J. Dynamic Relation Between Reduced, Oxidized, and Protein-Bound Homocysteine and Other Thiol Components in Plasma During Methionine Loading in Healthy Men. Clin Chem. 1992;38:1316-1321.
Hankey GJ, Eikelboom JW. Homocysteine and Vascular Disease. The Lancet. 1999; 354: 407-413.
Stamler JS, Osborne JA, Jaraji O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse Vascular Effects of Homocysteine are Modulated by Endothelium-Derived Relaxing Factor and Related Oxide of Nitrogen. J Clin Invest 1993; 91:308.
Welch GN, Loscalzo J. Homocysteine and Atherothrombosis: Review Article. N Engl J Med. 1998; 338:1042-1050.
Booth GL, & Wang EE. Preventive Health Care. Update: Screening and Management of Hyperhomocysteinemia for Prevention of Coronary Artery Disease Events. CMAJ. 2000; 163(1):21-29.
Widjayakusuma B, Mahindra HJ, Maskoen A, Achmad TH. Methylenetetrahydrofolate Reductase Polymorphism and
Homocysteine Levels in Indonesian Acute Myovardial Infarction Patients. In: Third International Conference on
Homocysteine Metabolism. 2001.
Santosa S, Delima ER, Prahastuti S, Lilyanti Linggajaya W, Prasetya E. Prevalensi Hiperhomosisteinemia pada Penderita Sindroma koroner akut di Rumah Sakit Immanuel Bandung. Dalam: A.W. Sudoyo (Ed) : Naskah Lengkap
KOPAPDI- XII 2003 Manado. Jakarta: Acta Medica Indonesiana; 2003; 670 -675.
Lim U, Cassano PA. Homocysteine and Blood Pressure in the Third National Health and Nutrition Examination Survey,
-1994. Am J Epidemiol. 2002; 156: 1105-1113.
Wald NJ, Law M, Morris JK. Homocysteine and Cardiovascular Disease: Evidence on Causality from a Meta-Analysis. BMJ. 2002; 325: 1202-1206.
The Homocysteine Studies Collaboration. Homocysteine and Risk of Ischemic Heart Disease andStroke. JAMA 2002;288:2015-2022.
Schindler K, Zauner C, Buchmayer H, Fodinger M, Wolfl G, Bieglmayer C, Heinz G, Wilfing A, Horl WH, Sunder-Plassman G. High Prevalence of Hyperhomocysteinemia in Critically Ill Patients. Crit Care Med. 2000; 28:991-995.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
